NEW DELHI: Strides Pharma Science Ltd will soon start its own clinical trial of potential covid-19 drug favirpiravir, becoming only the second firm in India to conduct a study on the broad-spectrum antiviral’s use in treating the fatal respiratory disease after Glenmark Pharmaceuticals Ltd. “We have the approval (from Drug Controller General of India) to conduct human study and we will be starting the studies soon," Strides Pharma founder and non-executive chairman Arun Kumar said on a post-earnings conference call on Thursday.
While Kumar said apex drug regulator, DCGI V.G. Somani, has approved the clinical trial, he did not give details on the number of sites that the trial will be conducted, or when it will start.